Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure.

PubWeight™: 1.76‹?› | Rank: Top 3%

🔗 View Article (PMID 17260106)

Published in Ann Surg Oncol on January 28, 2007

Authors

Alessandro Gronchi1, Rosalba Miceli, Marco Fiore, Paola Collini, Laura Lozza, Federica Grosso, Luigi Mariani, Paolo G Casali

Author Affiliations

1: Department of Surgery, Istituto Nazionale per lo studio e la cura dei Tumori, via Venezian, 1, 20133, Milano, Italy. alessandro.gronchi@istitutotumori.mi.it

Articles by these authors

MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98

Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med (2002) 12.83

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00

Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 5.62

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A (2009) 4.19

Outcome of different timings of radiotherapy in implant-based breast reconstructions. Plast Reconstr Surg (2011) 4.10

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology (2004) 3.61

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38

Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer (2006) 2.98

Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer (2011) 2.95

Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol (2007) 2.75

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol (2005) 2.68

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer (2005) 2.54

Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol (2009) 2.48

Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer (2004) 2.46

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology (2006) 2.38

Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia (2005) 2.37

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol (2012) 2.36

Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35

Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl (2011) 2.33

Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol (2008) 2.33

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg (2007) 2.30

Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg (2004) 2.20

Long-term renal outcome in adolescent and young adult patients nephrectomized for unilateral Wilms tumor. Pediatr Blood Cancer (2013) 2.19

Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol (2010) 2.14

Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer (2003) 2.11

Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU Int (2010) 2.08

Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98). Cancer (2013) 2.07

Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics (2005) 1.99

Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response. Ann Surg Oncol (2002) 1.97

Imatinib mesylate in chordoma. Cancer (2004) 1.94

Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma (2008) 1.85

Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol (2005) 1.83

Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene (2004) 1.82

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol (2012) 1.74

Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer (2005) 1.73

Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 1.68

Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res (2006) 1.66

Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg (2010) 1.62

Adult-type soft tissue sarcomas in pediatric-age patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol (2005) 1.61

Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med (2008) 1.61

Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers. J Thorac Oncol (2009) 1.61

Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer (2004) 1.61

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer (2012) 1.57

High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology (2009) 1.53

Local lymph node involvement in pediatric renal cell carcinoma: a report from the Italian TREP project. Pediatr Blood Cancer (2008) 1.52

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther (2009) 1.52

Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology. J Urol (2012) 1.51

Molecular classification of low-grade diffuse gliomas. Am J Pathol (2010) 1.51

Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol (2010) 1.49

Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol (2008) 1.49

RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Surgery (2002) 1.49

Postoperative complications in gastrointestinal cancer patients: the joint role of the nutritional status and the nutritional support. Clin Nutr (2007) 1.48

Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol (2009) 1.48

A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab (2007) 1.47

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J (2005) 1.47

Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet (2003) 1.47

Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res (2003) 1.46

Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol (2007) 1.46

Translocation-related sarcomas. Semin Oncol (2009) 1.45

Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer (2005) 1.45

Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44